Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 18.5% | -30.9% | 12.7% | – |
| Cost of Goods Sold | $0 | $0 | -$0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 92.6% | 90.2% | 102.7% | 92.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -331.7% | -527.5% | -430.3% | -540.6% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -353.8% | -561.9% | -445.7% | -553.3% |
| EPS | -9.09 | -12.2 | -14.02 | -15.48 |
| % Growth | 25.5% | 13% | 9.4% | – |
| EPS Diluted | -9.09 | -12.2 | -14.02 | -15.48 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -311.5% | -511.7% | -412.8% | -517.4% |